{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T10:59:59Z","timestamp":1776077999425,"version":"3.50.1"},"reference-count":140,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2021.0136","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T11:44:30Z","timestamp":1623239070000},"source":"Crossref","is-referenced-by-count":24,"title":["Bullous Autoimmune Dermatoses"],"prefix":"10.3238","author":[{"given":"Nina","family":"van Beek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Detlef","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enno","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2021,6,18]]},"reference":[{"key":"10.3238\/arztebl.m2021.0136_ref1","doi-asserted-by":"crossref","unstructured":"Schmidt E, Zillikens D: Pemphigoid diseases. Lancet 2013; 381: 320\u201332","DOI":"10.1016\/S0140-6736(12)61140-4"},{"key":"10.3238\/arztebl.m2021.0136_ref2","doi-asserted-by":"crossref","unstructured":"Schmidt E, Kasperkiewicz M, Joly P: Pemphigus. Lancet 2019; 394: 882\u201394","DOI":"10.1016\/S0140-6736(19)31778-7"},{"key":"10.3238\/arztebl.m2021.0136_ref3","doi-asserted-by":"crossref","unstructured":"Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al.: Pemphigus. Nat Rev Dis Primers 2017; 3: 17026","DOI":"10.1038\/nrdp.2017.26"},{"key":"10.3238\/arztebl.m2021.0136_ref4","doi-asserted-by":"crossref","unstructured":"Sardy M, Karpati S, Merkl B, Paulsson M, Smyth N: Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 2002; 195: 747\u201357","DOI":"10.1084\/jem.20011299"},{"key":"10.3238\/arztebl.m2021.0136_ref5","doi-asserted-by":"crossref","unstructured":"Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J: Bullous pemphigoid and pemphigus vulgaris\u2014incidence and mortality in the UK: population based cohort study. Bmj 2008; 337: a180","DOI":"10.1136\/bmj.a180"},{"key":"10.3238\/arztebl.m2021.0136_ref6","doi-asserted-by":"crossref","unstructured":"Hubner F, Konig IR, Holtsche MM, Zillikens D, Linder R, Schmidt E: Prevalence and age distribution of pemphigus and pemphigoid diseases among pediatric patients in Germany. J Eur Acad Dermatol Venereol 2020; 34: 2600\u20135","DOI":"10.1111\/jdv.16467"},{"key":"10.3238\/arztebl.m2021.0136_ref7","doi-asserted-by":"crossref","unstructured":"Anhalt GJ: Paraneoplastic pemphigus. J Investig Dermatol Symp Proc 2004; 9: 29\u201333","DOI":"10.1111\/j.1087-0024.2004.00832.x"},{"key":"10.3238\/arztebl.m2021.0136_ref8","doi-asserted-by":"crossref","unstructured":"Murrell DF, Daniel BS, Joly P, et al.: Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol 2012; 66: 479\u201385","DOI":"10.1016\/j.jaad.2011.06.032"},{"key":"10.3238\/arztebl.m2021.0136_ref9","doi-asserted-by":"crossref","unstructured":"Feliciani C, Joly P, Jonkman MF, et al.: Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol 2015; 172: 867\u201377","DOI":"10.1111\/bjd.13717"},{"key":"10.3238\/arztebl.m2021.0136_ref10","doi-asserted-by":"crossref","unstructured":"Schmidt E, Goebeler M, Hertl M, et al.: S2k guideline for the diagnosis of pemphigus vulgaris\/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges 2015; 13: 713\u201327","DOI":"10.1111\/ddg.12612"},{"key":"10.3238\/arztebl.m2021.0136_ref11","doi-asserted-by":"crossref","unstructured":"Kibsgaard L, Rasmussen M, Lamberg A, Deleuran M, Olesen AB, Vestergaard C: Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid. Br J Dermatol 2017; 176: 1486\u201391","DOI":"10.1111\/bjd.15405"},{"key":"10.3238\/arztebl.m2021.0136_ref12","doi-asserted-by":"crossref","unstructured":"Schulze F, Neumann K, Recke A, Zillikens D, Linder R, Schmidt E: Malignancies in pemphigus and pemphigoid diseases. J Invest Dermatol 2015; 135: 1445\u20137","DOI":"10.1038\/jid.2014.547"},{"key":"10.3238\/arztebl.m2021.0136_ref13","unstructured":"Kridin K, Cohen AD: Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid: a systematic review and meta-analysis. J Am Acad Dermatol 2018; S0190\u20139622(18)32660\u20134"},{"key":"10.3238\/arztebl.m2021.0136_ref14","doi-asserted-by":"crossref","unstructured":"Murrell DF, Marinovic B, Caux F, et al.: Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. J Am Acad Dermatol 2015; 72: 168\u201374","DOI":"10.1016\/j.jaad.2014.08.024"},{"key":"10.3238\/arztebl.m2021.0136_ref15","doi-asserted-by":"crossref","unstructured":"Goletz S, Probst C, Komorowski L, et al.: A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid. Br J Dermatol 2019; 180: 149\u201356","DOI":"10.1111\/bjd.17202"},{"key":"10.3238\/arztebl.m2021.0136_ref16","doi-asserted-by":"crossref","unstructured":"Vorobyev A, Ludwig RJ, Schmidt E: Clinical features and diagnosis of epidermolysis bullosa acquisita. Expert Rev Clin Immunol 2017; 13: 157\u201369","DOI":"10.1080\/1744666X.2016.1221343"},{"key":"10.3238\/arztebl.m2021.0136_ref17","doi-asserted-by":"crossref","unstructured":"Prost-Squarcioni C, Caux F, Schmidt E, et al.: International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita. Br J Dermatol 2018; 179: 30\u201341","DOI":"10.1111\/bjd.16138"},{"key":"10.3238\/arztebl.m2021.0136_ref18","doi-asserted-by":"crossref","unstructured":"G\u00f6r\u00f6g A, Antiga E, Caproni M, et al.: S2k guideline (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2021; 35:1251\u201377","DOI":"10.1111\/jdv.17183"},{"key":"10.3238\/arztebl.m2021.0136_ref19","doi-asserted-by":"crossref","unstructured":"van Beek N, Zillikens D, Schmidt E: Diagnostik blasenbildender Autoimmundermatosen. J Dtsch Dermatol Ges 2018; 16: 1077\u201392","DOI":"10.1111\/ddg.13637_g"},{"key":"10.3238\/arztebl.m2021.0136_ref20","doi-asserted-by":"crossref","unstructured":"Harman KE, Brown D, Exton LS, et al.: British Association of Dermatologists\u2018 guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol 2017; 177: 1170\u2013201","DOI":"10.1111\/bjd.15930"},{"key":"10.3238\/arztebl.m2021.0136_ref21","doi-asserted-by":"crossref","unstructured":"Hertl M, Jedlickova H, Karpati S, et al.: Pemphigus. S2 Guideline for diagnosis and treatment\u2014guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2015; 29: 405\u201314","DOI":"10.1111\/jdv.12772"},{"key":"10.3238\/arztebl.m2021.0136_ref22","doi-asserted-by":"crossref","unstructured":"Terra JB, Meijer JM, Jonkman MF, Diercks GF: The n- vs. u-serration is a learnable criterion to differentiate pemphigoid from epidermolysis bullosa acquisita in direct immunofluorescence serration pattern analysis. Br J Dermatol 2013; 169: 100\u20135","DOI":"10.1111\/bjd.12308"},{"key":"10.3238\/arztebl.m2021.0136_ref23","doi-asserted-by":"crossref","unstructured":"van Beek N, Kruger S, Fuhrmann T, et al.: Multicenter prospective \u2014study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP(TM) technology. J Am Acad Dermatol 2020; 83: 1315\u201322","DOI":"10.1016\/j.jaad.2020.01.049"},{"key":"10.3238\/arztebl.m2021.0136_ref24","doi-asserted-by":"crossref","unstructured":"Schmidt E, Sticherling M, Sardy M, et al.: S2k guidelines for the treatment of pemphigus vulgaris\/foliaceus and bullous pemphigoid: 2019 update. J Dtsch Dermatol Ges 2020; 18: 516\u201326","DOI":"10.1111\/ddg.14097"},{"key":"10.3238\/arztebl.m2021.0136_ref25","doi-asserted-by":"crossref","unstructured":"Spindler V, Eming R, Schmidt E, et al.: Mechanisms causing loss of keratinocyte cohesion in pemphigus. J Invest Dermatol 2018; 138: 32\u20137","DOI":"10.1016\/j.jid.2017.06.022"},{"key":"10.3238\/arztebl.m2021.0136_ref26","doi-asserted-by":"crossref","unstructured":"Chakievska L, Holtsche MM, Kunstner A, et al.: IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. J Autoimmun 2019; 96: 104\u201312","DOI":"10.1016\/j.jaut.2018.09.003"},{"key":"10.3238\/arztebl.m2021.0136_ref27","doi-asserted-by":"crossref","unstructured":"Kasprick A, Hofrichter M, Smith B, et al.: Treatment with anti-neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice. Br J Pharmacol 2020; 177: 2381\u201392","DOI":"10.1111\/bph.14986"},{"key":"10.3238\/arztebl.m2021.0136_ref28","doi-asserted-by":"crossref","unstructured":"Izumi K, Bieber K, Ludwig RJ: Current clinical trials in pemphigus and pemphigoid. Front Immunol 2019; 10: 978","DOI":"10.3389\/fimmu.2019.00978"},{"key":"10.3238\/arztebl.m2021.0136_ref29","doi-asserted-by":"crossref","unstructured":"Maglie R, Hertl M: Pharmacological advances in pemphigoid. Curr Opin Pharmacol 2019; 46: 34\u201343","DOI":"10.1016\/j.coph.2018.12.007"},{"key":"10.3238\/arztebl.m2021.0136_ref30","unstructured":"Rashid H, Lambert A, Alberti-Violetti S, et al.: S3 guideline on the diagnosis and management of mucous membrane pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV) \u2013 part I: Clinical presentation and outcome measurements for disease assessment. J Eur Acad Dermatol Venereol (in print)."},{"key":"10.3238\/arztebl.m2021.0136_ref31","doi-asserted-by":"crossref","unstructured":"Joly P, Horwath B, Patsatsi A, et al.: Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol 2020; 34: 1900\u201313","DOI":"10.1111\/jdv.16752"},{"key":"10.3238\/arztebl.m2021.0136_ref32","doi-asserted-by":"crossref","unstructured":"Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al.: First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet 2017; 389: 2031\u201340","DOI":"10.1016\/S0140-6736(17)30070-3"},{"key":"10.3238\/arztebl.m2021.0136_ref33","doi-asserted-by":"crossref","unstructured":"Ellebrecht CT, Bhoj VG, Nace A, et al.: Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 2016; 353: 179\u201384","DOI":"10.1126\/science.aaf6756"},{"key":"10.3238\/arztebl.m2021.0136_ref34","doi-asserted-by":"crossref","unstructured":"Joly P, Roujeau JC, Benichou J, et al.: A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346: 321\u20137","DOI":"10.1056\/NEJMoa011592"},{"key":"10.3238\/arztebl.m2021.0136_ref35","doi-asserted-by":"crossref","unstructured":"Sticherling M, Franke A, Aberer E, et al.: An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol 2017; 177: 1299\u2013305","DOI":"10.1111\/bjd.15649"},{"key":"10.3238\/arztebl.m2021.0136_ref36","doi-asserted-by":"crossref","unstructured":"Williams HC, Wojnarowska F, Kirtschig G, et al.: Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet 2017; 389: 1630\u20138","DOI":"10.1016\/S0140-6736(17)30560-3"},{"key":"10.3238\/arztebl.m2021.0136_ref37","doi-asserted-by":"crossref","unstructured":"Enk A, Hadaschik E, Eming R, et al.: European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. J Dtsch Dermatol Ges 2017; 15: 228\u201341","DOI":"10.1111\/ddg.13013"},{"key":"10.3238\/arztebl.m2021.0136_ref38","doi-asserted-by":"crossref","unstructured":"Kremer N, Snast I, Cohen ES, et al.: Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature. Am J Clin Dermatol 2019; 20: 209\u201316","DOI":"10.1007\/s40257-018-0401-6"},{"key":"10.3238\/arztebl.m2021.0136_ref39","doi-asserted-by":"crossref","unstructured":"Ujiie H, Iwata H, Yamagami J, et al.: Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita). J Dermatol 2019; 46: 1102\u201335","DOI":"10.1111\/1346-8138.15111"},{"key":"10.3238\/arztebl.m2021.0136_ref40","doi-asserted-by":"crossref","unstructured":"van Beek N, Weidinger A, Schneider SW, et al.: Incidence of pemphigoid diseases in Northern Germany in 2016\u2014first data from the Schleswig-Holstein Registry of autoimmune bullous diseases. J Eur Acad Dermatol Venereol 2021; 35: 1197\u2013202","DOI":"10.1111\/jdv.17107"},{"key":"10.3238\/arztebl.m2021.0136_ref41","doi-asserted-by":"crossref","unstructured":"Pollmann R, Schmidt T, Eming R, Hertl M: Pemphigus: a comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches. Clin Rev Allergy Immunol 2018; 54: 1\u201325","DOI":"10.1007\/s12016-017-8662-z"},{"key":"10.3238\/arztebl.m2021.0136_ref42","doi-asserted-by":"crossref","unstructured":"Amber KT, Murrell DF, Schmidt E, Joly P, Borradori L: Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management. Clin Rev Allergy Immunol 2018; 54: 26\u201351","DOI":"10.1007\/s12016-017-8633-4"},{"key":"10.3238\/arztebl.m2021.0136_ref43","doi-asserted-by":"crossref","unstructured":"Kridin K: Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Res 2018; 66: 255\u201370","DOI":"10.1007\/s12026-018-8986-7"},{"key":"10.3238\/arztebl.m2021.0136_ref44","doi-asserted-by":"crossref","unstructured":"Kridin K, Ludwig RJ: The growing incidence of bullous pemphigoid: overview and potential explanations. Front Med (Lausanne) 2018; 5: 220","DOI":"10.3389\/fmed.2018.00220"},{"key":"10.3238\/arztebl.m2021.0136_ref45","doi-asserted-by":"crossref","unstructured":"Bertram F, Brocker EB, Zillikens D, Schmidt E: Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 2009; 7: 434\u201340","DOI":"10.1111\/j.1610-0387.2008.06976.x"},{"key":"10.3238\/arztebl.m2021.0136_ref46","doi-asserted-by":"crossref","unstructured":"Marazza G, Pham HC, Scharer L, et al.: Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009; 161: 861\u20138","DOI":"10.1111\/j.1365-2133.2009.09300.x"},{"key":"10.3238\/arztebl.m2021.0136_ref47","doi-asserted-by":"crossref","unstructured":"Joly P, Baricault S, Sparsa A, et al.: Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol 2012; 132: 1998\u20132004","DOI":"10.1038\/jid.2012.35"},{"key":"10.3238\/arztebl.m2021.0136_ref48","doi-asserted-by":"crossref","unstructured":"Forsti AK, Jokelainen J, Timonen M, Tasanen K: Increasing incidence of bullous pemphigoid in Northern Finland: a retrospective database study in Oulu University Hospital. Br J Dermatol 2014; 171: 1223\u20136","DOI":"10.1111\/bjd.13189"},{"key":"10.3238\/arztebl.m2021.0136_ref49","doi-asserted-by":"crossref","unstructured":"Hubner F, Recke A, Zillikens D, Linder R, Schmidt E: Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany. J Invest Dermatol 2016; 136: 2495\u20138","DOI":"10.1016\/j.jid.2016.07.013"},{"key":"10.3238\/arztebl.m2021.0136_ref50","doi-asserted-by":"crossref","unstructured":"Jelti L, Cordel N, Gillibert A, et al.: Incidence and mortality of pemphigus in France. J Invest Dermatol 2019; 139: 469\u201373","DOI":"10.1016\/j.jid.2018.07.042"},{"key":"10.3238\/arztebl.m2021.0136_ref51","doi-asserted-by":"crossref","unstructured":"Joly P: Incidence of bullous pemphigoid and pemphigus vulgaris. BMJ 2008; 337: a209","DOI":"10.1136\/bmj.a209"},{"key":"10.3238\/arztebl.m2021.0136_ref52","doi-asserted-by":"crossref","unstructured":"Loget J, Barbe C, Duvert-Lehembre S, et al.: The regibul register: a tool for monitoring the distribution and incidence of autoimmune bullous dermatoses in three french regions, 2010 to 2015. Acta Derm Venereol 2018; 98: 380\u20131","DOI":"10.2340\/00015555-2848"},{"key":"10.3238\/arztebl.m2021.0136_ref53","doi-asserted-by":"crossref","unstructured":"Persson MSM, Harman KE, Vinogradova Y, et al.: Incidence, prevalence and mortality of bullous pemphigoid in England 1998\u20132017: a population-based cohort study. Br J Dermatol 2021; 184: 68\u201377","DOI":"10.1111\/bjd.19022"},{"key":"10.3238\/arztebl.m2021.0136_ref54","doi-asserted-by":"crossref","unstructured":"van Beek N, Schmidt E: Autoimmune bullous diseases. In: H\u00f6ger P, Kinsler V, Yan A (Eds) Harper\u2019s Textbook of Pediatric Dermatology, chapter 73, 4th edition Wiley-Blackwell, Chichester 2020: 868\u201397","DOI":"10.1002\/9781119142812.ch74"},{"key":"10.3238\/arztebl.m2021.0136_ref55","doi-asserted-by":"crossref","unstructured":"Sarig O, Bercovici S, Zoller L, et al.: Population-specific association between a polymorphic variant in ST18, encoding a pro-apoptotic molecule, and pemphigus vulgaris. J Invest Dermatol 2012; 132: 1798\u2013805","DOI":"10.1038\/jid.2012.46"},{"key":"10.3238\/arztebl.m2021.0136_ref56","doi-asserted-by":"crossref","unstructured":"Hirose M, Schilf P, Benoit S, et al.: Polymorphisms in the mitochondrially encoded ATP synthase 8 gene are associated with susceptibility to bullous pemphigoid in the German population. Exp Dermatol 2015; 24: 715\u20137","DOI":"10.1111\/exd.12732"},{"key":"10.3238\/arztebl.m2021.0136_ref57","doi-asserted-by":"crossref","unstructured":"Zimmermann J, Bahmer F, Rose C, Zillikens D, Schmidt E: Clinical and immunopathological spectrum of paraneoplastic pemphigus. J Dtsch Dermatol Ges 2010; 8: 598\u2013606","DOI":"10.1111\/j.1610-0387.2010.07380_supp.x"},{"key":"10.3238\/arztebl.m2021.0136_ref58","doi-asserted-by":"crossref","unstructured":"Yong AA, Tey HL: Paraneoplastic pemphigus. Australas J Dermatol 2013; 54: 241\u201350","DOI":"10.1111\/j.1440-0960.2012.00921.x"},{"key":"10.3238\/arztebl.m2021.0136_ref59","doi-asserted-by":"crossref","unstructured":"Leger S, Picard D, Ingen-Housz-Oro S, et al.: Prognostic factors of paraneoplastic pemphigus. Arch Dermatol 2012; 148: 1165\u201372","DOI":"10.1001\/archdermatol.2012.1830"},{"key":"10.3238\/arztebl.m2021.0136_ref60","doi-asserted-by":"crossref","unstructured":"Hashimoto T, Kiyokawa C, Mori O, et al.: Human desmocollin 1 (Dsc1) is an autoantigen for the subcorneal pustular dermatosis type of IgA pemphigus. J Invest Dermatol 1997; 109: 127\u201331","DOI":"10.1111\/1523-1747.ep12319025"},{"key":"10.3238\/arztebl.m2021.0136_ref61","doi-asserted-by":"crossref","unstructured":"Muller R, Heber B, Hashimoto T, et al.: Autoantibodies against desmocollins in European patients with pemphigus. Clin Exp Dermatol 2009; 34: 898\u2013903","DOI":"10.1111\/j.1365-2230.2009.03241.x"},{"key":"10.3238\/arztebl.m2021.0136_ref62","doi-asserted-by":"crossref","unstructured":"Hashimoto T, Teye K, Ishii N: Clinical and immunological studies of\u00a049 cases of various types of intercellular IgA dermatosis and 13\u00a0cases of classical subcorneal pustular dermatosis examined at Kurume University. Br J Dermatol 2017; 176: 168\u201375","DOI":"10.1111\/bjd.14780"},{"key":"10.3238\/arztebl.m2021.0136_ref63","doi-asserted-by":"crossref","unstructured":"Kasperkiewicz M, Kowalewski C, Jablonska S: Pemphigus herpetiformis: from first description until now. J Am Acad Dermatol 2014; 70: 780\u20137","DOI":"10.1016\/j.jaad.2013.11.043"},{"key":"10.3238\/arztebl.m2021.0136_ref64","doi-asserted-by":"crossref","unstructured":"della Torre R, Combescure C, Cortes B, et al.: Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort. Br J Dermatol 2012; 167: 1111\u20137","DOI":"10.1111\/j.1365-2133.2012.11108.x"},{"key":"10.3238\/arztebl.m2021.0136_ref65","doi-asserted-by":"crossref","unstructured":"Lamberts A, Meijer JM, Jonkman MF: Nonbullous pemphigoid: a systematic review. J Am Acad Dermatol 2018; 78: 989\u201395 e2","DOI":"10.1016\/j.jaad.2017.10.035"},{"key":"10.3238\/arztebl.m2021.0136_ref66","doi-asserted-by":"crossref","unstructured":"Kridin K, Bergman R: Assessment of the prevalence of mucosal involvement in bullous pemphigoid. JAMA Dermatol 2019; 155: 166\u201371","DOI":"10.1001\/jamadermatol.2018.5049"},{"key":"10.3238\/arztebl.m2021.0136_ref67","doi-asserted-by":"crossref","unstructured":"Forsti AK, Huilaja L, Schmidt E, Tasanen K: Neurological and psychiatric associations in bullous pemphigoid-more than skin deep? Exp Dermatol 2017; 26: 1228\u201334","DOI":"10.1111\/exd.13401"},{"key":"10.3238\/arztebl.m2021.0136_ref68","doi-asserted-by":"crossref","unstructured":"Bech R, Kibsgaard L, Vestergaard C: Comorbidities and treatment strategies in bullous pemphigoid: an appraisal of the existing litterature. Front Med (Lausanne) 2018; 5: 238","DOI":"10.3389\/fmed.2018.00238"},{"key":"10.3238\/arztebl.m2021.0136_ref69","doi-asserted-by":"crossref","unstructured":"Bastuji-Garin S, Joly P, Lemordant P, et al.: Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 2011; 131: 637\u201343","DOI":"10.1038\/jid.2010.301"},{"key":"10.3238\/arztebl.m2021.0136_ref70","doi-asserted-by":"crossref","unstructured":"Lloyd-Lavery A, Chi CC, Wojnarowska F, Taghipour K: The associations between bullous pemphigoid and drug use: a UK case-control study. JAMA Dermatol 2013; 149: 58\u201362","DOI":"10.1001\/2013.jamadermatol.376"},{"key":"10.3238\/arztebl.m2021.0136_ref71","doi-asserted-by":"crossref","unstructured":"Varpuluoma O, Forsti AK, Jokelainen J, et al.: Vildagliptin significantly increases the risk of bullous pemphigoid: a finnish nationwide registry study. J Invest Dermatol 2018; 138: 1659\u201361","DOI":"10.1016\/j.jid.2018.01.027"},{"key":"10.3238\/arztebl.m2021.0136_ref72","doi-asserted-by":"crossref","unstructured":"Plaquevent M, Tetart F, Fardet L, et al.: Higher frequency of dipeptidyl peptidase-4 inhibitor intake in bullous pemphigoid patients than in the french general population. J Invest Dermatol 2019; 139: 835\u201341","DOI":"10.1016\/j.jid.2018.10.045"},{"key":"10.3238\/arztebl.m2021.0136_ref73","doi-asserted-by":"crossref","unstructured":"Liu SD, Chen WT, Chi CC: Association between medication use and bullous pemphigoid: a systematic review and meta-analysis. JAMA Dermatol 2020; 156: 891\u2013900","DOI":"10.1001\/jamadermatol.2020.1587"},{"key":"10.3238\/arztebl.m2021.0136_ref74","doi-asserted-by":"crossref","unstructured":"Holtsche MM, Goletz S, van Beek N, et al.: Prospective study in bullous pemphigoid: association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score. Br J Dermatol 2018; 179: 918\u201324","DOI":"10.1111\/bjd.16553"},{"key":"10.3238\/arztebl.m2021.0136_ref75","doi-asserted-by":"crossref","unstructured":"Kridin K, Shihade W, Bergman R: Mortality in patients with bullous pemphigoid: a retrospective cohort study, systematic review and meta-analysis. Acta Derm Venereol 2019; 99: 72\u20137","DOI":"10.2340\/00015555-2930"},{"key":"10.3238\/arztebl.m2021.0136_ref76","doi-asserted-by":"crossref","unstructured":"Egan CA, Lazarova Z, Darling TN, Yee C, Cote T, Yancey KB: Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet 2001; 357: 1850\u20131","DOI":"10.1016\/S0140-6736(00)04971-0"},{"key":"10.3238\/arztebl.m2021.0136_ref77","doi-asserted-by":"crossref","unstructured":"Huilaja L, Makikallio K, Tasanen K: Gestational pemphigoid. Orphanet J Rare Dis 2014; 9: 136","DOI":"10.1186\/s13023-014-0136-2"},{"key":"10.3238\/arztebl.m2021.0136_ref78","doi-asserted-by":"crossref","unstructured":"Lammer J, Hein R, Roenneberg S, Biedermann T, Volz T: Drug-induced linear IgA bullous dermatosis: a case report and review of the literature. Acta Derm Venereol 2019; 99: 508\u201315","DOI":"10.2340\/00015555-3154"},{"key":"10.3238\/arztebl.m2021.0136_ref79","doi-asserted-by":"crossref","unstructured":"Goletz S, Hashimoto T, Zillikens D, Schmidt E: Anti-p200 pemphigoid. J Am Acad Dermatol 2014; 71: 185\u201391","DOI":"10.1016\/j.jaad.2014.02.036"},{"key":"10.3238\/arztebl.m2021.0136_ref80","doi-asserted-by":"crossref","unstructured":"Ludwig RJ: Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita. ISRN dermatology 2013; 2013: 812029","DOI":"10.1155\/2013\/812029"},{"key":"10.3238\/arztebl.m2021.0136_ref81","doi-asserted-by":"crossref","unstructured":"Meijer JM, Atefi I, Diercks GFH, et al.: Serration pattern analysis for differentiating epidermolysis bullosa acquisita from other pemphigoid diseases. J Am Acad Dermatol 2018; 78: 754\u201359.e6","DOI":"10.1016\/j.jaad.2017.11.029"},{"key":"10.3238\/arztebl.m2021.0136_ref82","doi-asserted-by":"crossref","unstructured":"Buijsrogge JJ, Diercks GF, Pas HH, Jonkman MF: The many faces of epidermolysis bullosa acquisita after serration pattern analysis by direct immunofluorescence microscopy. Br J Dermatol 2011; 165: 92\u20138","DOI":"10.1111\/j.1365-2133.2011.10346.x"},{"key":"10.3238\/arztebl.m2021.0136_ref83","doi-asserted-by":"crossref","unstructured":"Holtsche MM, Zillikens D, Schmidt E: [Mucous membrane pemphigoid]. Hautarzt 2018; 69: 67\u201383","DOI":"10.1007\/s00105-017-4089-y"},{"key":"10.3238\/arztebl.m2021.0136_ref84","doi-asserted-by":"crossref","unstructured":"Kaplan I, Hodak E, Ackerman L, Mimouni D, Anhalt GJ, Calderon S: Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol 2004; 40: 553\u201362","DOI":"10.1016\/j.oraloncology.2003.09.020"},{"key":"10.3238\/arztebl.m2021.0136_ref85","doi-asserted-by":"crossref","unstructured":"Sardy M, Kostaki D, Varga R, Peris K, Ruzicka T: Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid. J Am Acad Dermatol 2013; 69: 748\u201353","DOI":"10.1016\/j.jaad.2013.07.009"},{"key":"10.3238\/arztebl.m2021.0136_ref86","doi-asserted-by":"crossref","unstructured":"Blocker IM, Dahnrich C, Probst C, et al.: Epitope mapping of BP230 leading to a novel enzyme-linked immunosorbent assay for autoantibodies in bullous pemphigoid. Br J Dermatol 2012; 166: 964\u201370","DOI":"10.1111\/j.1365-2133.2012.10820.x"},{"key":"10.3238\/arztebl.m2021.0136_ref87","doi-asserted-by":"crossref","unstructured":"Schmidt E, Dahnrich C, Rosemann A, et al.: Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Exp Dermatol 2010; 19: 458\u201363","DOI":"10.1111\/j.1600-0625.2010.01069.x"},{"key":"10.3238\/arztebl.m2021.0136_ref88","doi-asserted-by":"crossref","unstructured":"Kobayashi M, Amagai M, Kuroda-Kinoshita K, et al.: BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 2002; 30: 224\u201332","DOI":"10.1016\/S0923-1811(02)00109-3"},{"key":"10.3238\/arztebl.m2021.0136_ref89","doi-asserted-by":"crossref","unstructured":"Saleh MA, Ishii K, Kim YJ, et al.: Development of NC1 and NC2 domains of type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients. J Dermatol Sci 2011; 62: 169\u201375","DOI":"10.1016\/j.jdermsci.2011.03.003"},{"key":"10.3238\/arztebl.m2021.0136_ref90","doi-asserted-by":"crossref","unstructured":"Sitaru C, Dahnrich C, Probst C, et al.: Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp Dermatol 2007; 16: 770\u20137","DOI":"10.1111\/j.1600-0625.2007.00592.x"},{"key":"10.3238\/arztebl.m2021.0136_ref91","unstructured":"van Beek N, Dahnrich C, Johannsen N, et al.: Prospective studies on the routine use of a novel multivariant enzyme-linked immunosorbent assay for the diagnosis of autoimmune bullous diseases. J Am Acad Dermatol 2017; 76: 889\u201394. e5."},{"key":"10.3238\/arztebl.m2021.0136_ref92","doi-asserted-by":"crossref","unstructured":"Ishii K, Amagai M, Hall RP, et al.: Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997; 159: 2010\u20137.","DOI":"10.4049\/jimmunol.159.4.2010"},{"key":"10.3238\/arztebl.m2021.0136_ref93","doi-asserted-by":"crossref","unstructured":"Charneux J, Lorin J, Vitry F, et al.: Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol 2011; 147: 286\u201391","DOI":"10.1001\/archdermatol.2011.23"},{"key":"10.3238\/arztebl.m2021.0136_ref94","doi-asserted-by":"crossref","unstructured":"Sadik CD, Pas HH, Bohlmann MK, et al.: Value of BIOCHIP technology in the serological diagnosis of pemphigoid gestationis. Acta Derm Venereol 2017; 97: 128\u201330","DOI":"10.2340\/00015555-2460"},{"key":"10.3238\/arztebl.m2021.0136_ref95","doi-asserted-by":"crossref","unstructured":"Murakami H, Nishioka S, Setterfield J, et al.: Analysis of antigens targeted by circulating IgG and IgA autoantibodies in 50 patients with cicatricial pemphigoid. J Dermatol Sci 1998; 17: 39\u201344","DOI":"10.1016\/S0923-1811(97)00067-4"},{"key":"10.3238\/arztebl.m2021.0136_ref96","doi-asserted-by":"crossref","unstructured":"Calabresi V, Carrozzo M, Cozzani E, et al.: Oral pemphigoid autoantibodies preferentially target BP180 ectodomain. Clin Immunol 2007; 122: 207\u201313","DOI":"10.1016\/j.clim.2006.10.007"},{"key":"10.3238\/arztebl.m2021.0136_ref97","doi-asserted-by":"crossref","unstructured":"Schmidt E, Skrobek C, Kromminga A, et al.: Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180. Br J Dermatol 2001; 145: 778\u201383","DOI":"10.1046\/j.1365-2133.2001.04471.x"},{"key":"10.3238\/arztebl.m2021.0136_ref98","doi-asserted-by":"crossref","unstructured":"Schmidt E, Obe K, Brocker EB, Zillikens D: Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000; 136: 174\u20138","DOI":"10.1001\/archderm.136.2.174"},{"key":"10.3238\/arztebl.m2021.0136_ref99","doi-asserted-by":"crossref","unstructured":"Kim JH, Kim YH, Kim S, et al.: Serum levels of anti-type VII collagen antibodies detected by enzyme-linked immunosorbent assay in patients with epidermolysis bullosa acquisita are correlated with the severity of skin lesions. J Eur Acad Dermatol Venereol 2012; 27: e224\u201330","DOI":"10.1111\/j.1468-3083.2012.04617.x"},{"key":"10.3238\/arztebl.m2021.0136_ref100","doi-asserted-by":"crossref","unstructured":"Horvath ON, Varga R, Kaneda M, Schmidt E, Ruzicka T, Sardy M: Diagnostic performance of the \u201eMESACUP anti-Skin profile TEST\u201c. Eur J Dermatol 2016; 26: 56\u201363","DOI":"10.1684\/ejd.2015.2692"},{"key":"10.3238\/arztebl.m2021.0136_ref101","doi-asserted-by":"crossref","unstructured":"van Beek N, Rentzsch K, Probst C, et al.: Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy. Orphanet J Rare Dis 2012; 7: 49","DOI":"10.1186\/1750-1172-7-49"},{"key":"10.3238\/arztebl.m2021.0136_ref102","doi-asserted-by":"crossref","unstructured":"Yang A, Xuan R, Melbourne W, Tran K, Murrell DF: Validation of the BIOCHIP test for the diagnosis of bullous pemphigoid, pemphigus vulgaris and pemphigus foliaceus. J Eur Acad Dermatol Venereol 2020; 34: 153\u201360","DOI":"10.1111\/jdv.15770"},{"key":"10.3238\/arztebl.m2021.0136_ref103","doi-asserted-by":"crossref","unstructured":"Komorowski L, Muller R, Vorobyev A, et al.: Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita. J Am Acad Dermatol 2012; 68: e89\u201395","DOI":"10.1016\/j.jaad.2011.12.032"},{"key":"10.3238\/arztebl.m2021.0136_ref104","doi-asserted-by":"crossref","unstructured":"Waschke J, Spindler V: Desmosomes and extradesmosomal adhesive signaling contacts in pemphigus. Med Res Rev 2014; 34: 1127\u201345","DOI":"10.1002\/med.21310"},{"key":"10.3238\/arztebl.m2021.0136_ref105","doi-asserted-by":"crossref","unstructured":"Hammers CM, Stanley JR: Mechanisms of disease: pemphigus and bullous pemphigoid. Annu Rev Pathol 2016; 11: 175\u201397","DOI":"10.1146\/annurev-pathol-012615-044313"},{"key":"10.3238\/arztebl.m2021.0136_ref106","doi-asserted-by":"crossref","unstructured":"Sadik CD, Schmidt E, Zillikens D, Hashimoto T: Recent progresses and perspectives in autoimmune bullous diseases. J Allergy Clin Immunol 2020; 145: 1145\u20137","DOI":"10.1016\/j.jaci.2020.02.020"},{"key":"10.3238\/arztebl.m2021.0136_ref107","doi-asserted-by":"crossref","unstructured":"Sadik CD, Zillikens D: Current treatments and developments in pemphigoid diseases as paradigm diseases for autoantibody-driven, organ-specific autoimmune diseases. Semin Hematol 2016; 53 (Suppl 1): S51\u20133","DOI":"10.1053\/j.seminhematol.2016.04.015"},{"key":"10.3238\/arztebl.m2021.0136_ref108","doi-asserted-by":"crossref","unstructured":"Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA: Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982; 306: 1189\u201396","DOI":"10.1056\/NEJM198205203062001"},{"key":"10.3238\/arztebl.m2021.0136_ref109","doi-asserted-by":"crossref","unstructured":"Amagai M, Tsunoda K, Suzuki H, Nishifuji K, Koyasu S, Nishikawa T: Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. J Clin Invest 2000; 105: 625\u201331","DOI":"10.1172\/JCI8748"},{"key":"10.3238\/arztebl.m2021.0136_ref110","doi-asserted-by":"crossref","unstructured":"Eming R, Hennerici T, Backlund J, et al.: Pathogenic IgG antibodies against desmoglein 3 in pemphigus vulgaris are regulated by HLA-DRB1*04:02-restricted T cells. J Immunol 2014; 193: 4391\u20139","DOI":"10.4049\/jimmunol.1401081"},{"key":"10.3238\/arztebl.m2021.0136_ref111","doi-asserted-by":"crossref","unstructured":"Liu Z, Diaz LA, Troy JL, et al.: A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993; 92: 2480\u20138","DOI":"10.1172\/JCI116856"},{"key":"10.3238\/arztebl.m2021.0136_ref112","doi-asserted-by":"crossref","unstructured":"Nishie W, Sawamura D, Goto M, et al.: Humanization of autoantigen. Nat Med 2007; 13: 378\u201383","DOI":"10.1038\/nm1496"},{"key":"10.3238\/arztebl.m2021.0136_ref113","doi-asserted-by":"crossref","unstructured":"Sitaru C, Mihai S, Otto C, et al.: Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest 2005; 115: 870\u20138","DOI":"10.1172\/JCI200521386"},{"key":"10.3238\/arztebl.m2021.0136_ref114","doi-asserted-by":"crossref","unstructured":"Haeberle S, Wei X, Bieber K, et al.: Regulatory T-cell deficiency leads to pathogenic bullous pemphigoid antigen 230 autoantibody and autoimmune bullous disease. J Allergy Clin Immunol 2018; 142: 1831\u201342. e7","DOI":"10.1016\/j.jaci.2018.04.006"},{"key":"10.3238\/arztebl.m2021.0136_ref115","doi-asserted-by":"crossref","unstructured":"Heppe EN, Tofern S, Schulze FS, et al.: Experimental laminin 332 mucous membrane pemphigoid critically involves C5aR1 and reflects clinical and immunopathological characteristics of the human disease. J Invest Dermatol 2017; 137: 1709\u201318","DOI":"10.1016\/j.jid.2017.03.037"},{"key":"10.3238\/arztebl.m2021.0136_ref116","doi-asserted-by":"crossref","unstructured":"Sadik CD, Schmidt E: Resolution in bullous pemphigoid. Semin Immunopathol 2019; 41: 645\u201354","DOI":"10.1007\/s00281-019-00759-y"},{"key":"10.3238\/arztebl.m2021.0136_ref117","doi-asserted-by":"crossref","unstructured":"Karsten CM, Pandey MK, Figge J, et al.: Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nat Med 2012; 18: 1401\u20136","DOI":"10.1038\/nm.2862"},{"key":"10.3238\/arztebl.m2021.0136_ref118","doi-asserted-by":"crossref","unstructured":"Koga H, Kasprick A, Lopez R, et al.: Therapeutic effect of a novel phosphatidylinositol-3-kinase delta inhibitor in experimental epidermolysis bullosa acquisita. Front Immunol 2018; 9: 1558","DOI":"10.3389\/fimmu.2018.01558"},{"key":"10.3238\/arztebl.m2021.0136_ref119","doi-asserted-by":"crossref","unstructured":"Samavedam UK, Mitschker N, Kasprick A, et al.: Whole-genome expression profiling in skin reveals SYK as a key regulator of inflammation in experimental epidermolysis bullosa acquisita. Front Immunol 2018; 9: 249","DOI":"10.3389\/fimmu.2018.00249"},{"key":"10.3238\/arztebl.m2021.0136_ref120","doi-asserted-by":"crossref","unstructured":"Stussel P, Dieckhoff KS, Kunzel S, et al.: Propranolol is an effective topical and systemic treatment option for experimental epidermolysis bullosa acquisita. J Invest Dermatol 2020; 140: 2408\u201320","DOI":"10.1016\/j.jid.2020.04.025"},{"key":"10.3238\/arztebl.m2021.0136_ref121","doi-asserted-by":"crossref","unstructured":"Gunther C, Wozel G, Meurer M, Pfeiffer C: Up-regulation of CCL11 and CCL26 is associated with activated eosinophils in bullous pemphigoid. Clin Exp Immunol 2011; 166: 145\u201353","DOI":"10.1111\/j.1365-2249.2011.04464.x"},{"key":"10.3238\/arztebl.m2021.0136_ref122","doi-asserted-by":"crossref","unstructured":"Shrikhande M, Hunziker T, Braathen LR, Pichler WJ, Dahinden CA, Yawalkar N: Increased coexpression of eotaxin and interleukin 5 in bullous pemphigoid. Acta Derm Venereol 2000; 80: 277\u201380","DOI":"10.1080\/000155500750012162"},{"key":"10.3238\/arztebl.m2021.0136_ref123","doi-asserted-by":"crossref","unstructured":"Wakugawa M, Nakamura K, Hino H, et al.: Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia. Br J Dermatol 2000; 143: 112\u20136","DOI":"10.1046\/j.1365-2133.2000.03599.x"},{"key":"10.3238\/arztebl.m2021.0136_ref124","unstructured":"Schmidt E, Lambert A, Marzano A, et al.: S3 guideline on the diagnosis and management of mucous membrane pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol (in preparation)."},{"key":"10.3238\/arztebl.m2021.0136_ref125","doi-asserted-by":"crossref","unstructured":"Lee A, Sandhu S, Imlay-Gillespie L, Mulligan S, Shumack S: Successful use of Bruton\u2018s kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia. Australas J Dermatol 2017; 58: e240-e2","DOI":"10.1111\/ajd.12615"},{"key":"10.3238\/arztebl.m2021.0136_ref126","doi-asserted-by":"crossref","unstructured":"Hofrichter M, Dworschak J, Emtenani S, et al.: Immunoadsorption o f desmoglein-3-specific IgG abolishes the blister-inducing capacity of pemphigus vulgaris IgG in neonatal mice. Front Immunol 2018; 9: 1935","DOI":"10.3389\/fimmu.2018.01935"},{"key":"10.3238\/arztebl.m2021.0136_ref127","doi-asserted-by":"crossref","unstructured":"Hubner F, Kasperkiewicz M, Knuth-Rehr D, et al.: Adjuvant treatment of severe\/refractory bullous pemphigoid with protein A immunoadsorption. J Dtsch Dermatol Ges 2018; 16: 1109\u201318","DOI":"10.1111\/ddg.13642"},{"key":"10.3238\/arztebl.m2021.0136_ref128","doi-asserted-by":"crossref","unstructured":"Bastuji-Garin S, Souissi R, Blum L, et al.: Comparative epidemiology of pemphigus in Tunisia and France: unusual incidence of pemphigus foliaceus in young Tunisian women. J Invest Dermatol 1995; 104: 302\u20135","DOI":"10.1111\/1523-1747.ep12612836"},{"key":"10.3238\/arztebl.m2021.0136_ref129","unstructured":"Stanley J: Pemphigus. In: Wolff K GL, Katz SI, et al. (ed.): Fitzpatrick\u2019s dermatology in general medicine. New York: McGraw-Hill 2008; p. p. 459\u201368."},{"key":"10.3238\/arztebl.m2021.0136_ref130","doi-asserted-by":"crossref","unstructured":"Bernard P, Vaillant L, Labeille B, et al.: Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 1995; 131: 48\u201352","DOI":"10.1001\/archderm.131.1.48"},{"key":"10.3238\/arztebl.m2021.0136_ref131","doi-asserted-by":"crossref","unstructured":"Radford CF, Rauz S, Williams GP, Saw VP, Dart JK: Incidence, presenting features, and diagnosis of cicatrising conjunctivitis in the United Kingdom. Eye (Lond) 2012; 26: 1199\u2013208","DOI":"10.1038\/eye.2012.119"},{"key":"10.3238\/arztebl.m2021.0136_ref132","doi-asserted-by":"crossref","unstructured":"Milinkovic MV, Jankovic S, Medenica L, et al.: Incidence of autoimmune bullous diseases in Serbia: a 20-year retrospective study. J Dtsch Dermatol Ges 2016; 14: 995\u20131005","DOI":"10.1111\/ddg.13081"},{"key":"10.3238\/arztebl.m2021.0136_ref133","doi-asserted-by":"crossref","unstructured":"van Beek N, Knuth-Rehr D, Altmeyer P, et al.: Diagnostics of autoimmune bullous diseases in German dermatology departments. J Dtsch Dermatol Ges 2012; 10: 492\u20139","DOI":"10.1111\/j.1610-0387.2011.07840.x"},{"key":"10.3238\/arztebl.m2021.0136_ref134","doi-asserted-by":"crossref","unstructured":"Tsuruta D, Ishii N, Hamada T, et al.: IgA pemphigus. Clin Dermatol 2011; 29: 437\u201342","DOI":"10.1016\/j.clindermatol.2011.01.014"},{"key":"10.3238\/arztebl.m2021.0136_ref135","doi-asserted-by":"crossref","unstructured":"Kridin K, Patel PM, Jones VA, Cordova A, Amber KT: IgA pemphigus: a systematic review. J Am Acad Dermatol 2020; 82: 1386\u201392","DOI":"10.1016\/j.jaad.2019.11.059"},{"key":"10.3238\/arztebl.m2021.0136_ref136","doi-asserted-by":"crossref","unstructured":"Wojnarowska F, Kirtschig G, Khumalo N: Treatment of subepidermal immunobullous diseases. Clin Dermatol 2001; 19: 768\u201377","DOI":"10.1016\/S0738-081X(00)00189-9"},{"key":"10.3238\/arztebl.m2021.0136_ref137","doi-asserted-by":"crossref","unstructured":"Kasperkiewicz M, Meier M, Zillikens D, Schmidt E: Linear IgA disease: successful application of immunoadsorption and review of the literature. Dermatology 2010; 220: 259\u201363","DOI":"10.1159\/000279318"},{"key":"10.3238\/arztebl.m2021.0136_ref138","doi-asserted-by":"crossref","unstructured":"Iwata H, Vorobyev A, Koga H, et al.: Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients. Orphanet J Rare Dis 2018; 13: 153","DOI":"10.1186\/s13023-018-0896-1"},{"key":"10.3238\/arztebl.m2021.0136_ref139","doi-asserted-by":"crossref","unstructured":"Santi CG, Gripp AC, Roselino AM, et al.: Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita\u2014 Brazilian Society of Dermatology. An Bras Dermatol 2019; 94: 33\u201347","DOI":"10.1590\/abd1806-4841.2019940207"},{"key":"10.3238\/arztebl.m2021.0136_ref140","doi-asserted-by":"crossref","unstructured":"Hahn-Ristic K, Rzany B, Amagai M, Br\u00f6cker E-B, Zillikens D: Increased incidence of pemphigus vulgaris in southern Europeans living in Germany compared with native Germans. Eur Acad Dermatol Venereol 2002; 16:68\u201371","DOI":"10.1046\/j.1468-3083.2002.00384.x"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2021.0136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T18:11:03Z","timestamp":1699121463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2021.0136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,18]]},"references-count":140,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2021.0136","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,18]]}}}